Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Introduction
-
1. Psychopharmacology: structural aspects of the brain
- Prof. Brian Leonard
-
2. The nature of chemical neurotransmission
- Prof. Brian Leonard
-
3. Psychotropic drugs
- Prof. Brian Leonard
-
4. Psychopharmacology of anxiety disorders
- Prof. Brian Leonard
-
5. Psychopharmacology of depression
- Prof. Brian Leonard
-
6. Psychopharmacology of mania and schizophrenia
- Prof. Brian Leonard
-
7. The role of stress and immune system in psychiatric disorders
- Prof. Brian Leonard
- Introduction to Genetic Investigations of Complex Traits
- Genetics and Pharmacokinetics of Psychotropic Drugs
-
9. Genetics of phase I enzymes
- Prof. Aiming Yu
-
10. Phase II metabolism
- Prof. Ann Daly
- Genetics and Pharmacodynamics of Psychotropic Drugs
-
13. Pharmacogenetics of antidepressants
- Prof. Alessandro Serretti
- Clinical Applications of Psychopharmacogenetics
-
14. Of genes and drugs: genetic determinants of adverse drug reactions
- Dr. Mario Masellis
-
15. Cocaine and amphetamine addiction genetics
- Dr. Gerome Breen
- Archived Lectures *These may not cover the latest advances in the field
-
18. Genetic determinants of metabolism: clinical applications in psychiatry
- Prof. Julia Stingl (formerly Kirchheiner)
-
20. Genetic polymorphisms influencing response to lithium
- Prof. Alessandro Serretti
-
21. Genetic determinants of antipsychotic-induced weight gain
- Prof. Gavin Reynolds
-
24. Genetic determinants of agranulocytosis
- Dr. Michael Dettling
-
25. Genetic polymorphisms influencing the response of antidepressants
- Prof. Alessandro Serretti
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline (Index)
- First part (Intro)
- Pharmacological treatment in psychiatry
- Causes of treatment variability
- Biological interactions
- Neurotransmitter receptor
- Influence of neurotransmitter receptor variants
- Genetic influence on drug-target interactions (1)
- Genetic influence on drug-target interactions (2)
- Pharmacological profile of psychotropics
- Genetic influence on dopaminergic interactions
- Dopaminergic system
- D2 occupancy and drug response
- Dopamine receptor genes
- Dopamine genetic variants and treatment efficacy
- Dopamine genetic variants and side effects
- Genetic influence on serotonergic interactions
- Serotonergic system
- 5-HT2A receptor gene (HTR2A)
- 5-HT2A receptor
- 5-HT2A and -1438-G/A: Influence on expression
- 5-HT2A His452Tyr functional effect
- 5-HT2A meta analysis
- 5-HT2A polymorphisms and side effects
- 5-HT2C receptor
- 5-HT2C receptor gene (HTR2C)
- Genetic influence of weight gain
- 5-HTT (SLC6A4)
- Meta analyses in Caucasians (SSRIs)
- Gene and environment interactions
- 5-HTT and antidepressant induced mania
- Serotonin genetic variants and treatment efficacy
- Serotonin genetic variants and side effects
- Dopamine & serotonin: symptom associations
- Genetic influence: other neurotransmitter systems
- Other receptor variants and treatment outcome
- Final part (summing up)
- Genetic associations with treatment efficacy
- Pharmacogenetic associations with side effects
- Talk summary
- References
- References (2)
- References (3)
Topics Covered
- Pharmacological treatment in psychiatry
- Causes of treatment variability
- Genetic influence on drug-target interactions
- Pharmacological profile of psychotropics
- The dopaminergic system and drug response
- Genetic influence on dopaminergic interactions
- The dopaminergic system and drug response
- Genetic influence on serotonergic interactions
- Genetic variants and associations with treatment efficacy and side effects
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Arranz, M. (2014, December 2). Influence of neurotransmitter receptor variants on interactions with psychotropic drugs [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/IGKQ9719.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Maria Arranz has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Influence of neurotransmitter receptor variants on interactions with psychotropic drugs
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
This talk, we
focus on influence of genetic
variants in neurotransmitter
receptors on the response with
treatment with psychotropic drugs.
0:10
The talk is divided into five parts,
starting with a brief introduction.
A second part is dedicated
to genetic variants
in dopamine receptors
and transporters
and the influence on
treatment response.
The third chapter summarizes
the effect of genetic variants
in the serotonergic system, followed
by a chapter on genetic variants
in other neurotransmitter
systems and their influence
on clinical outcome.
0:35
Introduction-- The
mainstay treatment
0:38
of severe mental disorders, such
as schizophrenia and bipolar
disorders, is the use
of psychotropic drugs.
However, not all patients
respond to treatment.
30 to 50% of treated
patients fail to respond.
And about 60 to 70%
of treated patients
develop long lasting
and severe side effects,
which can be life threatening.
1:05
The causes of treatment variability
are a combination of genetic,
environmental, and clinical factors.
A limited number of
family and genetic studies
support the contribution
of genetic factors
to the variability in treatment
response to psychotropic treatment,
although no extensive
treatment study
has been performed to
quantify their contribution.
There is also evidence suggesting
that environmental and clinical
factors influence treatment
response, factors such as smoking,
food, plasma levels, therapeutic
doses, concomitant treatment,
especially when patients are
treated with several drug
substrates for the
same metabolic enzyme.
Ethnicity, age and gender of the
patient, the severity of illness,
all have been suggested to
contribute to treatment response,
however, none of mentioned
clinical and environmental factors
can reliably predict
treatment response.
And it is thought that interaction
between genetic and non-genetic
factors results in
treatment variability.
Hide